20000 3467-8
For Reference

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :		(11) International Publication Number:
A61K 31/00	**A2**	**WO 99/40904**
		(43) International Publication Date: 19 August 1999 (19.08.99)

(21) International Application Number: PCT/EP99/00614

(22) International Filing Date: 30 January 1999 (30.01.99)

(30) Priority Data:
98/01709 12 February 1998 (12.02.98) FR

(71) Applicant *(for all designated States except US)*: MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250, D–64293 Darmstadt (DE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BONHOMME, Yves [FR/FR]; 21 avenue de la Paix, F–69260 Charbonnières les Bains (FR). BRIET, Philippe [FR/FR]; 216, avenue Félix Faure, F–69003 Lyon (FR).

(74) Common Representative: MERCK PATENT GMBH; Postfach, D–64271 Darmstadt (DE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

pls file away.

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METFORMIN AND FIBRATE, AND ITS USE FOR THE PREPARATION OF MEDICINES INTENDED TO REDUCE HYPERGLYCAEMIA

(57) Abstract

The present invention relates to a pharmaceutical composition comprising, as active principles, (i) metformin optionally in the form of one of its pharmaceutically acceptable salts, and (ii) a fibrate chosen from fenofibrate and bezafibrate, in combination with one or more pharmaceutically acceptable excipients. These compositions are particularly suitable for the treatment of non–insulin–dependent diabetes.